BACKGROUND: Peptides from alpha-gliadins have been used to characterise the immunodominant coeliac toxic epitope. A peptide corresponding to amino acid residues 57-73 of A-gliadin causes peripheral blood mononuclear cells from coeliac patients to secrete interferon gamma (IFN-gamma); gluten specific small intestinal T cell clones proliferate in response to peptides corresponding to residues 57-68 and 62-75 of alpha-gliadins. We wished to investigate whether a peptide corresponding to residues 56-75 of alpha-gliadins exacerbates coeliac disease in vivo. METHODS: Four adults with coeliac disease, all of whom were on a gluten free diet, underwent three challenges. Peptic-tryptic gliadin (PTG 1 g) served as a positive control. The test peptide and a negative control peptide were studied on separate occasions. The peptides were instilled into the duodenum and biopsies were taken before the infusion, and two, four, and six hours after commencing the infusions, using a Quinton hydraulic multiple biopsy capsule. Biopsy specimens were assessed blindly for villus height to crypt depth ratio (VH:CD), enterocyte cell height (ECH), and intraepithelial lymphocyte (IEL) count. We used the Mann-Whitney U test, with 95% confidence intervals, for statistical analysis. RESULTS: VH:CD and ECH fell, and IEL increased significantly 4-6 hours after commencing infusions with both PTG and the test peptide in all subjects. The negative control peptide caused no significant changes to villus morphology, enterocyte height, or IEL count in any patient. CONCLUSION: We have confirmed that the putative immunodominant epitope, a peptide corresponding to residues 56-75 of alpha-gliadins, exacerbates coeliac disease in vivo.
BACKGROUND: Peptides from alpha-gliadins have been used to characterise the immunodominant coeliac toxic epitope. A peptide corresponding to amino acid residues 57-73 of A-gliadin causes peripheral blood mononuclear cells from coeliac patients to secrete interferon gamma (IFN-gamma); gluten specific small intestinal T cell clones proliferate in response to peptides corresponding to residues 57-68 and 62-75 of alpha-gliadins. We wished to investigate whether a peptide corresponding to residues 56-75 of alpha-gliadins exacerbates coeliac disease in vivo. METHODS: Four adults with coeliac disease, all of whom were on a gluten free diet, underwent three challenges. Peptic-tryptic gliadin (PTG 1 g) served as a positive control. The test peptide and a negative control peptide were studied on separate occasions. The peptides were instilled into the duodenum and biopsies were taken before the infusion, and two, four, and six hours after commencing the infusions, using a Quinton hydraulic multiple biopsy capsule. Biopsy specimens were assessed blindly for villus height to crypt depth ratio (VH:CD), enterocyte cell height (ECH), and intraepithelial lymphocyte (IEL) count. We used the Mann-Whitney U test, with 95% confidence intervals, for statistical analysis. RESULTS: VH:CD and ECH fell, and IEL increased significantly 4-6 hours after commencing infusions with both PTG and the test peptide in all subjects. The negative control peptide caused no significant changes to villus morphology, enterocyte height, or IEL count in any patient. CONCLUSION: We have confirmed that the putative immunodominant epitope, a peptide corresponding to residues 56-75 of alpha-gliadins, exacerbates coeliac disease in vivo.
Authors: A Picarelli; M Di Tola; L Sabbatella; M C Anania; T Di Cello; R Greco; M Silano; M De Vincenzi Journal: Scand J Gastroenterol Date: 1999-11 Impact factor: 2.423
Authors: Y van de Wal; Y M Kooy; P van Veelen; W Vader; S A August; J W Drijfhout; S A Peña; F Koning Journal: Eur J Immunol Date: 1999-10 Impact factor: 5.532
Authors: H Lähteenoja; M Mäki; M Viander; I Räihä; P Vilja; I Rantala; A Toivanen; S Syrjänen Journal: Am J Gastroenterol Date: 2000-10 Impact factor: 10.864
Authors: H Arentz-Hansen; R Körner; O Molberg; H Quarsten; W Vader; Y M Kooy; K E Lundin; F Koning; P Roepstorff; L M Sollid; S N McAdam Journal: J Exp Med Date: 2000-02-21 Impact factor: 14.307
Authors: A Camarca; G Radano; R Di Mase; G Terrone; F Maurano; S Auricchio; R Troncone; L Greco; C Gianfrani Journal: Clin Exp Immunol Date: 2012-08 Impact factor: 4.330